On January 27, 2021, Design Therapeutics, a biotechnology company developing new therapies for degenerative disorders caused by nucleotide repeat expansions, announced the successful completion of a $125 million Series B financing, led by Logos Capital, a biotechnology-focused investment fund. Wilson Sonsini Goodrich & Rosati advised Logos Capital in the financing.

According to the press release, proceeds from the financing will be used to advance Design Therapeutics’ novel GeneTAC platform, which leverages the disease modifying potential of genomic medicines with proprietary advances in transcriptional regulation chemistry, to create a pipeline of GeneTAC molecules. The company’s initial focus is on developing medicines for the treatment of nucleotide repeat expansion disorders, including Friedreich ataxia and myotonic dystrophy type-1.

The Wilson Sonsini team advising Logos Capital in the financing includes partner Dan Koeppen, associate Meghan Burton, and venture counsel Bridget Balisy.

Please see Design Therapeutics’ press release for more information.